Table 1.
Summary of the demographic, clinical and therapeutic characteristics of SLE patients
| At blood-sampling time | |||||
|---|---|---|---|---|---|
| Patient | Sex | Age (years) | Diagnosis according to ARA criteria | SLEDAI | Treatment |
| With quiescent disease | |||||
| 1 | F | 30 | A, Sk,P | 6 | Pred = 20 mg, Hycl |
| 2 | F | 27 | Bl, A | 4 | Pred < 10 mg |
| 3 | F | 25 | Sk, Bl | 2 | Pred = 20 mg |
| 4 | F | 54 | A, Bl | 6 | Pred = 20 mg |
| 5 | F | 21 | A, Sk | 4 | None |
| 6 | F | 59 | Sk, A | 6 | Pred = 25 mg |
| 7 | F | 22 | P, A, NP | 6 | Pred = 10 mg, Hycl |
| 8 | F | 36 | P, A | 2 | Hycl |
| 9 | F | 71 | A, Sk, APS | 4 | Pred = 20 mg |
| 10 | F | 16 | A, NP | 4 | Pred = 15 mg |
| 11 | F | 45 | Bl, A | 3 | Pred < 10 mg |
| 12 | F | 46 | A, Sk, APS | 6 | None |
| 13 | F | 33 | NP, Sk | 2 | None |
| 14 | M | 33 | Sk, A | 6 | Pred > 15 mg |
| 15 | F | 24 | K, Sk, A | 6 | Pred = 10 mg, Aza |
| 16 | F | 50 | A, P | 6 | NSAID |
| 17 | F | 31 | Bl, APS, Sk | 4 | None |
| 18 | F | 22 | A, P | 4 | Pred = 15 mg |
| 19 | F | 26 | K, A | 4 | Pred < 10 mg, Aza |
| 20 | F | 34 | K, A | 4 | Pred = 10 mg |
| 21 | F | 25 | A, Sk | 2 | None |
| 22 | F | 32 | A, K, P | 2 | None |
| 23 | F | 31 | A, Sk | 4 | Hycl |
| 24 | F | 50 | P, A | 2 | Pred < 10 mg |
| 25 | F | 41 | Bl, A, NP | 5 | Pred < 10 mg, Hycl |
| 26 | F | 59 | Sk, A, APS | 3 | None |
| 27 | F | 40 | A, Sk, Bl | 3 | None |
| 28 | M | 44 | P, Bl | 2 | None |
| 29 | F | 41 | APS, A, P | 3 | Pred > 12·5 mg, Aza |
| 30 | F | 74 | A, P, Bl | 2 | Pred = 15 mg |
| 31 | F | 48 | APS, NP | 1 | Pred = 30 mg |
| 32 | F | 30 | Sk, A, APS | 2 | Pred < 10 mg |
| 33 | F | 30 | Sk, Bl, APS | 2 | None |
| 34 | F | 40 | Sk, A, Bl | 3 | None |
| With active disease | |||||
| 101 | M | 79 | K, A | 12 | None |
| 102 | F | 38 | A, P | 12 | None |
| 103 | F | 40 | Sk, A, K | 27 | None |
| 104 | F | 19 | Sk, A | 10 | None |
| 105 | F | 29 | Sk, A | 8 | Pred < 10 mg |
| 106 | M | 23 | A* K* | 25 | NSAID |
| 107 | F | 32 | A*, K*, Sk | 23 | Pred < 10 mg, Aza |
| 108 | F | 26 | A, P | 15 | None |
| 109 | F | 28 | K*, A* | 18 | Pred. = 20 mg |
| 110 | F | 21 | A*, Sk* | 10 | Pred < 10 mg |
| 111 | F | 28 | A*, Sk, P* | 11 | Pred < 10 mg |
| 112 | F | 31 | NP, A | 12 | Pred < 10 mg |
| 113 | F | 38 | A*, Sk* | 9 | Pred < 10 mg, Hycl |
| 114 | F | 65 | Bl, NP*, P | 18 | Pred < 10 mg, Aza |
| 115 | F | 52 | P, A | 8 | Pred < 10 mg |
| 116 | F | 45 | A*, Sk* | 11 | Pred < 10 mg |
| 117 | F | 29 | A*, Sk* | 10 | NSAID |
| 118 | F | 35 | K, P, Bl | 23 | None |
| 119 | F | 16 | Bl, A | 9 | None |
| 120 | F | 36 | A, Sk | 12 | NSAID |
| 121 | F | 30 | NP*, A | 25 | Pred = 15 mg, Hycl |
| 122 | F | 71 | Bl, Sk, A | 12 | None |
| 123 | F | 37 | A, P | 8 | None |
| 124 | F | 55 | Sk*, A*, Bl* | 12 | NSAID |
| 125 | F | 20 | A, APS, Bl | 12 | None |
| 126 | F | 64 | A*, Bl* | 8 | Pred < 10 mg |
*
Organ affected during the flare (only for the patients having a SLE before the flare; for the others, all mentioned organs in the ARA criteria are involved because it is at diagnosis). A, musculoskeletal system; K, renal disease; Sk, mucocutaneous lesions; Bl, haematological abnormality; NP, neuropsychiatric disorders; P, pericarditis; APS, antiphospholipid syndrome. Pred, prednisone expressed as dose/24 h; Aza, Azathioprine; Hycl, Hydroxychloroquine; NSAID, nonsteroidal anti-inflammatory drug.